You can seek FDA approval to launch a generic drug before the expiration of ABILIFY MAINTENA KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABILIFY MAINTENA KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABILIFY MAINTENA KIT:-

You can seek FDA approval to launch a generic drug before the expiration of AMRIX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AMRIX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AMRIX:-

You can seek FDA approval to launch a generic drug before the expiration of CONTRAVE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CONTRAVE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CONTRAVE:-

You can seek FDA approval to launch a generic drug before the expiration of FORTEO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FORTEO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FORTEO:-

You can seek FDA approval to launch a generic drug before the expiration of GLUMETZA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GLUMETZA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GLUMETZA:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of KAZANO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the KAZANO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on KAZANO:-

You can seek FDA approval to launch a generic drug before the expiration of LUMIGAN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LUMIGAN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LUMIGAN:-

You can seek FDA approval to launch a generic drug before the expiration of LYSTEDA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LYSTEDA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LYSTEDA:-

You can seek FDA approval to launch a generic drug before the expiration of MEKTOVI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MEKTOVI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MEKTOVI:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of NESINA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NESINA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NESINA:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of OXAYDO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the OXAYDO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on OXAYDO:-

You can seek FDA approval to launch a generic drug before the expiration of SPIRIVA RESPIMAT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SPIRIVA RESPIMAT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SPIRIVA RESPIMAT:-

You can seek FDA approval to launch a generic drug before the expiration of VELTASSA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VELTASSA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VELTASSA:-

You can seek FDA approval to launch a generic drug before the expiration of VIBERZI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VIBERZI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VIBERZI:-

You can seek FDA approval to launch a generic drug before the expiration of XARELTO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XARELTO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XARELTO:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of XIIDRA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XIIDRA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XIIDRA:-

You can seek FDA approval to launch a generic drug before the expiration of XTAMPZA ER's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XTAMPZA ER's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XTAMPZA ER:-

You can seek FDA approval to launch a generic drug before the expiration of YUPELRI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the YUPELRI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on YUPELRI:-